Erythropoietin modulates imbalance of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in doxorubicin-induced cardiotoxicity

Heart Lung and Circulation

Volumn 23, Issue 8, 2014, Pages 772-777

  Chen, Xing ^a   Guo, Zhihua ^b   Wang, Peixian ^c   Xu, Miqing ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Department of Pharmacy Guangdong Women and Children Hospital ^*  (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cardiotoxicity; Doxorubicin; Erythropoietin; Fibrosis; Matrix metalloproteinase; Tissue inhibitor of metalloproteinase

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CARDIOTOXIN; DOXORUBICIN; ERYTHROPOIETIN; GELATINASE A; MMP2 PROTEIN, RAT; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DOWN REGULATION; DRUG EFFECTS; FIBROSIS; HEART DISEASE; MALE; METABOLISM; PATHOLOGY; RAT; TIME; UPREGULATION; WISTAR RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTOXINS; DOWN-REGULATION; DOXORUBICIN; ERYTHROPOIETIN; FIBROSIS; HEART DISEASES; MALE; MATRIX METALLOPROTEINASE 2; RATS; RATS, WISTAR; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UP-REGULATION;

EID: 84904991704     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.02.015     Document Type: Article

References (30)

1. Nakamura R., Takahashi A., Yamada T., Miyai N., Irie H., Kinoshita N., et al. Erythropoietin in patients with acute coronary syndrome and its cardioprotective action after percutaneous coronary intervention. Circ J 2009, 73(10):1920-1926.
2. Watson A.J., Gao L., Sun L., Tsun J., Jabbour A., Ru Qiu M., et al. Enhanced preservation of the rat heart after prolonged hypothermic ischemia with erythropoietin-supplemented Celsior solution. J Heart Lung Transplant 2013, 32(6):633-640.
3. Gut N., Piecha G., Aldebssi F., Schaefer S., Bekeredjian R., Schirmacher P., et al. Erythropoietin combined with ACE inhibitor prevents heart remodeling in 5/6 nephrectomized rats independently of blood pressure and kidney function. Am J Nephrol 2013, 38(2):124-135.
4. Zhuo X.Z., Wu Y., Ni Y.J., Liu J.H., Gong M., Wang X.H., et al. Isoproterenol instigates cardiomyocyte apoptosis and heart failure via AMPK inactivation-mediated endoplasmic reticulum stress. Apoptosis 2013, 18(7):800-810.
5. Yang D.C., Ma S.T., Tan Y., Chen Y.H., Li D., Tang B., et al. Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Cardiology 2010, 116(2):133-141.
6. Horn M.A., Graham H.K., Richards M.A., Clarke J.D., Greensmith D.J., Briston S.J., et al. Age-related divergent remodeling of the cardiac extracellular matrix in heart failure: collagen accumulation in the young and loss in the aged. J Mol Cell Cardiol 2012, 53(1):82-90.
7. Mandi A., Huong Pham L., Toth K., Zambetti G., Erhardt P. Puma deletion delays cardiac dysfunction in murine heart failure models through attenuation of apoptosis. Circulation 2011, 124(1):31-39.
8. Wang X.L., Wang X., Xiong L.L., Zhu Y., Chen H.L., Chen J.X., et al. Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. J Cardiovasc Pharmacol 2013, 62(6):512-523.
9. Mong M.C., Hsia T.C., Yin M.C. Dietary trans fats enhance doxorubicin-induced cardiotoxicity in mice. J Food Sci 2013, 78(10):H1621-H1628.
10. Schunke K.J., Coyle L., Merrill G.F., Denhardt D.T. Acetaminophen attenuates doxorubicin-induced cardiac fibrosis via osteopontin and GATA4 regulation: reduction of oxidant levels. J Cell Physiol 2013, 228(10):2006-2014.
11. Mohammadi Goriji S., Karimpor Malekshah A.A., Hashemi-Soteh M.B., Rafiei A., Parivar K., Aqhdami N. Effect of mesenchymal stem cells on doxorubicin-induced fibrosis. Cell J 2012, 14(2):142-151.
12. Feridooni T., Hotchkiss A., Remley-Carr S., Saga Y., Pasumarthi K.B. Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS One 2011, 6(7):e22801.
13. Miljus N., Heibeck S., Jarrar M., Micke M., Ostrowski D., Ehrenreich H., et al. Erythropoietin-mediated protection of insect brain neurons involves JAK and STAT but not PI3K transduction pathways. Neuroscience 2014, 258:218-227.
14. Hu M.C., Shi M., Cho H.J., Zhang J., Pavlenco A., Liu S., et al. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int 2013, 84(3):468-481.
15. Pan Y., Shu J.L., Gu H.F., Zhou D.C., Liu X.L., Qiao Q.Y., et al. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T2L1 adipocytes. Mol Cell Endocrinol 2013, 367(1-2):116-123.
16. Kong D., Zhuo L., Gao C., Shi S., Wang N., Huang Z., et al. Erythropoietin protects against cisplatin-induced nephrotoxicity by attenuating endoplasmic reticulum stress-induced apoptosis. J Nephrol 2013, 26(1):219-227.
17. Hellewell S.C., Yan E.B., Alwis D.S., Bye N., Morqanti-Kossmann M.C. Erythropoietin improves motor and cognitive deficit, axonal pathology, and neuroinflammation in a combined model of diffuse traumatic brain injury and hypoxia, in association with upregulation of the erythropoietin receptor. J Neuroinflammation 2013, 10(1):156.
18. Mitsuhashi J., Morikawa S., Shimizu K., Ezaki T., Yasuda Y., Hori S. Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats. Exp Eye Res 2013, 106:64-73.
19. Ammar H.I., Saba S., Ammar R.I., Elsayed L.A., Ghaly W.B., Dhingra S. Erythropoietin protects against doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol 2011, 301(6):H2413-H2421.
20. Weng S., Zhu X., Jin Y., Wang T., Huang H. Protective effect of erythropoietin on myocardial infarction in rats by inhibition of caspase-12 expression. Exp Ther Med 2011, 2(5):833-836.
21. Tsoutsman T., Wang X., Garchow K., Riser B., Twigg S., Semsarian C. CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure. J Mol Cell Cardiol 2013, 62:164-178.
22. Kwak H.B., Kim J.H., Joshi K., Yeh A., Martinez D.A., Lawler J.M. Exercise training reduces fibrosis and matrix metalloproteinase dysregulation in the aging rat heart. FASEB J 2011, 25(3):1106-1117.
23. Szardien S., Mollmann H., Willmer M., Liebetrau C., Voss S., Troidl C., et al. Molecular basis of disturbed extracellular matrix homeostasis in stress cardiomyopathy. Int J Cardiol 2013, 168(2):1685-1688.
24. Siasos G., Tousoulis D., Kioufis S., Oikonomou E., Siasou Z., Limperi M., et al. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases. Curr Top Med Chem 2012, 12(10):1132-1148.
25. Sterba M., Popelova O., Lenco J., Fucikova A., Brcakova E., Mazurova Y., et al. Proteomic insights into chronic anthracycline cardiotoxicity. J Mol Cell Cardiol 2011, 50(5):849-862.
26. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002, 90(5):520-530.
27. Berman M., Teerlink J., Li L., Zhu B.Q., Nquyen A., Dahi S., et al. Cardiac matrix metalloproteinase-2 expression independently induced marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007, 292(4):H1847-H1860.
28. Van Linthout S., Seeland U., Riad A., Eckhardt O., Hohl M., Dhayat N., et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2008, 103(4):319-327.
29. Souvenir R., Fathali N., Ostrowski R.P., Lekic T., Zhang J.H., Tang J. Tissue inhibitor of matrix metalloproteinase-1 mediates erythropoietin-induced neuroprotection in hypoxia ischemia. Neurobiol Dis 2011, 44(1):28-37.
30. Xu Y., Tian Y., Wei H.J., Chen J., Dong J.F., Zacharek A., et al. Erythropoietin increases circulating endothelial progenitor cells and reduces the formation and progression of cerebral aneurysm in rats. Neuroscience 2011, 181(10):292-299.